Drug Profile


Alternative Names: Anti-Notch 2/3; Anti-Notch 2/3 monoclonal antibody; OMP-59R5; TRXT

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OncoMed Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Notch-2 receptor antagonists; Notch-3 receptor antagonists; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer; Small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 17 Apr 2017 OncoMed Pharmaceuticals completes the phase Ib/II PINNACLE trial in Small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease) in USA (NCT01859741)
  • 17 Apr 2017 Top-line results from the phase Ib/II PINNACLE trial in Small cell lung cancer released by OncoMed Pharmaceuticals
  • 05 Apr 2017 Pharmacodynamics data from the phase Ib/II PINNACLE trial in Small cell lung cancer presented at the American Association for Cancer Research Annual Meeting (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top